Advancements and New Treatment Options: Optimizing Care for Patients with Graft-vs-Host Disease : Episode 1

Opinion

Video

February 28, 2024

Overview of Graft-vs-Host Disease (GvHD)

Author(s):

Hana Safah, MD,Corey S. Cutler, MD, MPH, FRCPC

Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.

Now Viewing

EP: 1.Overview of Graft-vs-Host Disease (GvHD)

EP: 2.How Does GvHD Typically Present?

EP: 3.Role of Biomarkers in Graft-vs-Host Disease

EP: 4.Staging Practices for Chronic Graft-vs-Host Disease

EP: 5.First-Line Therapy for Chronic GvHD

EP: 6.Treating Patients With Steroid-Refractory Chronic GvHD

EP: 7.Approved Therapies for Steroid-Refractory Chronic GvHD

EP: 8.Therapies in Development for Chronic GvHD

EP: 9.Supportive Care and Medication Access in GvHD

Related Content

December 3rd 2024

OncLive’s November Roundup of Key FDA Approvals in Oncology

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

December 2nd 2024

Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

November 29th 2024

Obe-Cel Approval Expands CAR T-Cell Therapy Options in Relapsed/Refractory ALL